Skip to main content

Table 1 Characteristics of 765 high-risk women at cohort enrolment, according to HIV-1 serostatus

From: Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study

Characteristic HIV seronegative (N = 492) n (%) HIV-1 seropositive (N = 273) n (%) P-valuea
Age groups, years (N = 759)    
   16-24 265 (54.1) 53 (19.7) <0.001b
   25-34 138 (28.2) 124 (46.1)  
   ≥35 87 (17.8) 92 (34.2)  
Education (N = 752)    
   None 189 (38.8) 116 (44.8) 0.19
   Primary or above 298 (61.2) 149 (56.2)  
Marital status (N = 754)    
   Widowed 14 (2.9) 55 (20.8) <0.001a
   Divorced/Separated 70 (14.3) 50 (18.9)  
   Married/cohabitating 88 (18.0) 58 (21.9)  
   Single 317 (64.8) 102 (38.5)  
Age at first sex, median (IQR), years 16 (15-18) 16 (15-18) 0.42b
Number of sex partners in last week (N = 752)    
   None 110 (22.5) 114 (43.2) <0.001b
   1-9 309 (63.3) 120 (45.5)  
   ≥10 69 (14.1) 30 (11.4)  
Currently smoking (N = 759) 25 (5.1) 19 (7.0) 0.30
Contraceptive use (N = 760)    
Other/None 405 (83.2) 249 (91.2) 0.002
   Hormonal contraception 68 (14.0) 19 (7.0)  
   Injectable contraception 14 (2.8) 5 (1.8)  
Practices regular vaginal douching 424 (86.2) 222 (81.3) 0.24
Condom use with clients/partners (N = 751)    
   Sometimes/Never 177 (36.0) 98 (35.9)  
   Always 315 (64.0) 175 (64.1) 0.98
Current genital warts 8 (1.6) 19 (7.0) <0.001
Bacterial vaginosis (N = 718) 178 (37.2) 118 (49.2) 0.003
Trichomonas vaginalis (N = 596) 29 (7.2) 19 (9.6) 0.32
HSV-2 positive serology (N = 689) 226 (49.6) 204 (88.3) <0.001
Current antiretroviral therapy (HAART)   26 (9.5)  
CD4+ count, cells/μL :    
   Not on HAART (N = 242)    
>500   81 (33.5) 0.09a,e
200-500   105 (43.4)  
<200   56 (23.1)  
   On HAART (N = 25)    
>500   4 (16.0)  
200-500   11 (44.0)  
<200   10 (40.0)  
Plasma HIV-1 RNA, log10 copies/mL d:    
   Not on HAART (N = 233)    
≥2.48   204 (87.6) <0.001a,e
<2.48   29 (12.4)  
   On HAART (N = 24)    
≥2.48   7 (29.2)  
<2.48   17 (70.82)  
Cervical HPV-6 or -11 (N = 306)f 13 (7.1) 15 (12.2) 0.13
LSIL (N = 306)f 17 (9.4) 48 (41.4) <0.001
HSIL (N = 306)f 1 (0.6) 11 (9.5)  
  1. IQR, interquartile range; HAART, highly active antiretroviral therapy; CI, confidence interval; HPV, human papillomavirus; LSIL/HSIL, low/high grade squamous intraepithelial lesions.
  2. a Determined by χ2 analysis; b Determined by χ2 test of trend; c Nonparametric equality of medians test; d Lower limit of detection of HIV-1 PVL is 2.48 log10 copies/mL; e Comparison of women on HAART vs not on HAART; f Conducted in subset of women.